Neuropeptides (VIP, alpha-MSH/KPV, CGRP, cortistatin) as therapeutic approaches for autoimmune diseases including RA, MS, and IBD — comprehensive 2010 review of the anti-autoimmune neuropeptide therapeutic landscape.
Key findingNeuropeptides (VIP, alpha-MSH/KPV, CGRP, cortistatin) as therapeutic approaches for autoimmune diseases including RA, MS, and IBD — comprehensive 2010
What the researchers found
Neuropeptides (VIP, alpha-MSH/KPV, CGRP, cortistatin) as therapeutic approaches for autoimmune diseases including RA, MS, and IBD — comprehensive 2010 review of the anti-autoimmune neuropeptide therapeutic landscape.
Why it matters
Relevant for peptide research.
How the study worked
research study.
What this study cannot tell us
See abstract.
How to read the evidence
emerging evidence.
When this study was published
Published in 2010.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
Common questions
What was studied?
What was found?
Read the original research
Neuropeptides as therapeutic approach to autoimmune diseases.
Current pharmaceutical design, 16(28), 3158-72
Citation
Gonzalez-Rey, Elena; Delgado-Maroto, Virginia; Souza Moreira, Luciana; Delgado, Mario. (2010). Neuropeptides as therapeutic approach to autoimmune diseases.. Current pharmaceutical design, 16(28), 3158-72.